Financing
Kesmalea becomes Oyster Therapeutics and raises $60 million for tau degraders
The London protein-degrader company, now called Oyster Therapeutics, has raised $60 million in a Series A-2 round led by 4BIO Capital. The money will push its lead tau degrader, an oral drug designed to reach the brain, toward the clinic and support the SELFTAC platform. Oyster is also funding tau biology research at Massachusetts General Hospital.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.